We have updated our Online Services Terms of Use and Privacy Policy. See our Cookies Notice for information concerning our use of cookies and similar technologies. By using this website or clicking “I ACCEPT”, you consent to our Online Services Terms of Use.

COVID-19 Study for Children

A Study of Nirmatrelvir/Ritonavir in Pediatric, Non-Hospitalized Symptomatic Participants with COVID-19 Who are at Risk of Progression to Severe Disease.

little boy blowing his nose
AGE: 6-17 years old
TYPE: Interventional Treatment Study
LOCATIONS: University Hospitals Rainbow Babies & Children’s

Learn More About This Research Study

For more information, please contact Sarah Hornung at 216-983-0832 or complete the online form below.

Purpose of the Study

The purpose of this study is to test the safety and efficacy of Nirmatrelvir/Ritonavir, for non-hospitalized children diagnosed with COVID-19 who are at risk of progression to severe COVID disease and have at least one underlying medical condition (i.e. obesity, neurodevelopmental disorders, immunosuppressive disease, chronic lung disease, cardiovascular disease, or kidney disease, hypertension, diabetes, sickle cell disease, etc.).

Who Can Participate

Participants between 6-17 years of age with at least one symptom of COVID-19 and have at least one underlying medical condition (i.e., overweight, current smoker, immunosuppressive disease, chronic lung, heart, or kidney disease, hypertension (high blood pressure), Type 1 or Type 2 Diabetes , Sickle Cell Disease, etc.) may be eligible for this study.

Request More Information

To learn more about this study, please fill out the form below to request more information.

I'm not a robot